Vicore Pharma Holding AB (publ) (FRA:6Y4)

Germany flag Germany · Delayed Price · Currency is EUR
0.9300
-0.0260 (-2.72%)
At close: Feb 20, 2026
Market Cap282.10M +56.8%
Revenue (ttm)768.92K -91.8%
Net Income-38.39M
EPS-0.17
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.9300
Previous Close0.9560
Day's Range0.9300 - 0.9300
52-Week Range0.5210 - 1.1820
Betan/a
RSI42.40
Earnings DateFeb 27, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 36
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6Y4
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements